Tags

Type your tag names separated by a space and hit enter

Plasma bikunin as a favorable prognostic factor in ovarian cancer.
J Clin Oncol. 2005 Mar 01; 23(7):1463-72.JC

Abstract

PURPOSE

Bikunin is a multifunctional glycoprotein, which mediates suppression of tumor cell invasion and metastasis. The measurement of bikunin levels in the tissue of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the evaluation of prognosis. The high bikunin expression in ovarian cancer tissue would enable the use of soluble bikunin protein present in the circulation of ovarian cancer patients as a biomarker of disease.

PATIENTS AND METHODS

We developed a double-antibody immunoassay for bikunin and detected its presence in normal human circulation. We quantified, by enzyme-linked immunosorbent assay and/or immunoblot assay bikunin in sera from 200 healthy women (controls), 200 patients with benign gynecologic diseases, and 327 patients with ovarian cancer before surgical removal of the tumor.

RESULTS

When the values of bikunin corresponding to the median were used as the cutoff value (11.5 microg/mL), low plasma bikunin was strongly associated with late-stage, suboptimal debulking with large residual tumor (> 2 cm) and low response to chemotherapy. The median survival time of the patients with a high bikunin level was more than 60 months as compared with 26 months among those with low bikunin level (P = .002). This difference corresponded to a 2.2-fold increased risk of dying for the lower plasma bikunin patients (hazard ratio, 0.45; P = .023) and remained significant in multivariate analysis (hazard ratio, 0.63; P = .041).

CONCLUSION

Preoperative plasma bikunin concentration is a strong and independent favorable prognostic marker for ovarian cancer.

Authors+Show Affiliations

Netforce Co Ltd., Nakamura, Aichi, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15735122

Citation

Matsuzaki, Hidenori, et al. "Plasma Bikunin as a Favorable Prognostic Factor in Ovarian Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 23, no. 7, 2005, pp. 1463-72.
Matsuzaki H, Kobayashi H, Yagyu T, et al. Plasma bikunin as a favorable prognostic factor in ovarian cancer. J Clin Oncol. 2005;23(7):1463-72.
Matsuzaki, H., Kobayashi, H., Yagyu, T., Wakahara, K., Kondo, T., Kurita, N., Sekino, H., Inagaki, K., Suzuki, M., Kanayama, N., & Terao, T. (2005). Plasma bikunin as a favorable prognostic factor in ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 23(7), 1463-72.
Matsuzaki H, et al. Plasma Bikunin as a Favorable Prognostic Factor in Ovarian Cancer. J Clin Oncol. 2005 Mar 1;23(7):1463-72. PubMed PMID: 15735122.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma bikunin as a favorable prognostic factor in ovarian cancer. AU - Matsuzaki,Hidenori, AU - Kobayashi,Hiroshi, AU - Yagyu,Tatsuo, AU - Wakahara,Kiyoshi, AU - Kondo,Toshiharu, AU - Kurita,Noriyuki, AU - Sekino,Hideo, AU - Inagaki,Kiyokazu, AU - Suzuki,Mika, AU - Kanayama,Naohiro, AU - Terao,Toshihiko, PY - 2005/3/1/pubmed PY - 2005/3/26/medline PY - 2005/3/1/entrez SP - 1463 EP - 72 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 23 IS - 7 N2 - PURPOSE: Bikunin is a multifunctional glycoprotein, which mediates suppression of tumor cell invasion and metastasis. The measurement of bikunin levels in the tissue of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the evaluation of prognosis. The high bikunin expression in ovarian cancer tissue would enable the use of soluble bikunin protein present in the circulation of ovarian cancer patients as a biomarker of disease. PATIENTS AND METHODS: We developed a double-antibody immunoassay for bikunin and detected its presence in normal human circulation. We quantified, by enzyme-linked immunosorbent assay and/or immunoblot assay bikunin in sera from 200 healthy women (controls), 200 patients with benign gynecologic diseases, and 327 patients with ovarian cancer before surgical removal of the tumor. RESULTS: When the values of bikunin corresponding to the median were used as the cutoff value (11.5 microg/mL), low plasma bikunin was strongly associated with late-stage, suboptimal debulking with large residual tumor (> 2 cm) and low response to chemotherapy. The median survival time of the patients with a high bikunin level was more than 60 months as compared with 26 months among those with low bikunin level (P = .002). This difference corresponded to a 2.2-fold increased risk of dying for the lower plasma bikunin patients (hazard ratio, 0.45; P = .023) and remained significant in multivariate analysis (hazard ratio, 0.63; P = .041). CONCLUSION: Preoperative plasma bikunin concentration is a strong and independent favorable prognostic marker for ovarian cancer. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/15735122/Plasma_bikunin_as_a_favorable_prognostic_factor_in_ovarian_cancer_ L2 - https://ascopubs.org/doi/10.1200/JCO.2005.03.010?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -